^
Phase N/A
China-Japan Friendship Hospital
Completed
Last update posted :
10/21/2021
Initiation :
12/01/2016
Primary completion :
12/01/2019
Completion :
05/01/2020
Phase 1
Stanford University
Recruiting
Last update posted :
10/21/2021
Initiation :
09/07/2021
Primary completion :
06/01/2024
Completion :
06/01/2024
HLA-DRB1
|
melphalan • fludarabine IV • Mozobil (plerixafor) • Neupogen (filgrastim) • tacrolimus XR • tacrolimus intravenous
Phase 3
Wuhan Union Hospital, China
Recruiting
Last update posted :
10/21/2021
Initiation :
09/14/2021
Primary completion :
10/13/2023
Completion :
10/13/2024
CD19
|
fludarabine IV
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Not yet recruiting
Last update posted :
10/21/2021
Initiation :
12/01/2021
Primary completion :
12/01/2025
Completion :
12/01/2026
AR
|
abiraterone acetate • Xofigo (radium Ra-223 dichloride)
Phase N/A
Emory University
Recruiting
Last update posted :
10/21/2021
Initiation :
11/01/2021
Primary completion :
08/01/2022
Completion :
08/01/2022
Phase 2
Harvard Medical School
Not yet recruiting
Last update posted :
10/21/2021
Initiation :
09/15/2022
Primary completion :
02/14/2024
Completion :
02/14/2025
Phase 1b/2
Abbisko Therapeutics Co, Ltd
Recruiting
Last update posted :
10/21/2021
Initiation :
06/03/2021
Primary completion :
08/14/2023
Completion :
05/27/2024
FGFR2
|
FGFR2 mutation
|
ABSK-091
Phase N/A
Aydin Adnan Menderes University
Completed
Last update posted :
10/21/2021
Initiation :
07/01/2021
Primary completion :
08/30/2021
Completion :
09/30/2021
Phase 3
Novo Nordisk A/S
Recruiting
Last update posted :
10/21/2021
Initiation :
03/16/2021
Primary completion :
03/15/2023
Completion :
04/25/2023
Phase 3
Novo Nordisk A/S
Recruiting
Last update posted :
10/21/2021
Initiation :
08/30/2021
Primary completion :
09/24/2025
Completion :
10/15/2025
Phase 2
Peking University People's Hospital
Recruiting
Last update posted :
10/21/2021
Initiation :
10/20/2021
Primary completion :
01/01/2023
Completion :
10/01/2023
Phase 3
WestVac Biopharma Co., Ltd.
Enrolling by invitation
Last update posted :
10/21/2021
Initiation :
06/15/2021
Primary completion :
02/28/2022
Completion :
12/31/2022
Phase N/A
Seoul National University Hospital
Recruiting
Last update posted :
10/21/2021
Initiation :
10/05/2021
Primary completion :
09/01/2024
Completion :
12/01/2024
Phase 
Fudan University
Recruiting
Last update posted :
10/21/2021
Initiation :
12/01/2020
Primary completion :
09/09/2022
Completion :
09/09/2022
Phase N/A
Shanghai Chest Hospital
Enrolling by invitation
Last update posted :
10/21/2021
Initiation :
09/28/2021
Primary completion :
06/01/2024
Completion :
12/01/2024
Phase 1/2
Medicenna Therapeutics, Inc.
Recruiting
Last update posted :
10/21/2021
Initiation :
08/27/2021
Primary completion :
09/30/2024
Completion :
12/30/2024
Phase 3
Fundación Instituto de Estudios de Ciencias de ...
Active, not recruiting
Last update posted :
10/21/2021
Initiation :
05/26/2021
Primary completion :
12/01/2025
Completion :
12/01/2025
Phase N/A
UMC Utrecht
Enrolling by invitation
Last update posted :
10/21/2021
Initiation :
07/05/2021
Primary completion :
04/01/2026
Completion :
04/01/2026
ADCYAP1
Phase 2a
NeoTX Therapeutics Ltd.
Recruiting
Last update posted :
10/21/2021
Initiation :
07/29/2021
Primary completion :
06/01/2023
Completion :
10/01/2023
EGFR
|
docetaxel • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
Phase 4
Sanofi
Not yet recruiting
Last update posted :
10/21/2021
Initiation :
10/15/2021
Primary completion :
12/10/2022
Completion :
02/02/2023
CD34
|
Mozobil (plerixafor)
Phase 1
Shanghai Pharmaceuticals Holding Co., Ltd
Recruiting
Last update posted :
10/21/2021
Initiation :
07/10/2020
Primary completion :
09/30/2022
Completion :
03/30/2023
MET • HGF
Phase N/A
Abramson Cancer Center of the University of Pen...
Not yet recruiting
Last update posted :
10/21/2021
Initiation :
01/01/2022
Primary completion :
06/30/2026
Completion :
06/30/2026
MGMT
|
MGMT promoter methylation
Phase 3
GlaxoSmithKline
Recruiting
Last update posted :
10/21/2021
Initiation :
06/28/2021
Primary completion :
02/05/2025
Completion :
08/24/2029
HER-2 • HRD • BRCA
|
HER-2 negative • HRD • BRCA mutation
|
Zejula (niraparib)
Phase N/A
Next Biomedical Co., Ltd.
Recruiting
Last update posted :
10/21/2021
Initiation :
05/31/2021
Primary completion :
05/30/2023
Completion :
05/30/2023
CRP
Phase 
M.D. Anderson Cancer Center
Recruiting
Last update posted :
10/21/2021
Initiation :
08/22/2019
Primary completion :
12/31/2021
Completion :
12/31/2021
Phase 1
Peking Union Medical College Hospital
Not yet recruiting
Last update posted :
10/21/2021
Initiation :
11/01/2021
Primary completion :
09/01/2022
Completion :
09/01/2023
Phase 2
Eunice Kennedy Shriver National Institute of Ch...
Recruiting
Last update posted :
10/20/2021
Initiation :
10/25/2021
Primary completion :
10/01/2024
Completion :
10/01/2025
Phase N/A
Nordsjaellands Hospital
Not yet recruiting
Last update posted :
10/21/2021
Initiation :
12/01/2021
Primary completion :
04/01/2022
Completion :
04/01/2022
Phase 2
National Institute of Allergy and Infectious Di...
Not yet recruiting
Last update posted :
10/21/2021
Initiation :
10/15/2021
Primary completion :
03/01/2022
Completion :
03/01/2023
Phase 3
AbbVie
Not yet recruiting
Last update posted :
10/21/2021
Initiation :
12/10/2021
Primary completion :
03/06/2027
Completion :
03/09/2027
EGFR • MET
|
EGFR mutation • MET overexpression
|
docetaxel • telisotuzumab vedotin (ABBV-399)
Phase 2
Hebei Medical University Fourth Hospital
Recruiting
Last update posted :
10/21/2021
Initiation :
10/15/2021
Primary completion :
05/15/2024
Completion :
05/15/2026
Phase 2
Novartis Pharmaceuticals
Not yet recruiting
Last update posted :
10/21/2021
Initiation :
11/08/2021
Primary completion :
08/14/2023
Completion :
09/18/2025
Phase 2
Marcelo Pasquini, MD
Not yet recruiting
Last update posted :
10/21/2021
Initiation :
10/01/2021
Primary completion :
04/01/2023
Completion :
02/01/2025
CD34
|
Revlimid (lenalidomide) • Abecma (idecabtagene vicleucel)
Phase 2
PETHEMA Foundation
Recruiting
Last update posted :
10/21/2021
Initiation :
04/07/2021
Primary completion :
03/01/2025
Completion :
07/01/2025
CD34
|
Revlimid (lenalidomide) • bortezomib • dexamethasone • melphalan • Blenrep (belantamab mafodotin)
Phase 2
Checkmate Pharmaceuticals
Recruiting
Last update posted :
10/20/2021
Initiation :
02/10/2021
Primary completion :
02/01/2023
Completion :
02/01/2023
BRAF
|
BRAF mutation • BRAF V600
|
Opdivo (nivolumab) • vidutolimod (CMP-001)
Phase 3
Novo Nordisk A/S
Recruiting
Last update posted :
10/21/2021
Initiation :
07/22/2021
Primary completion :
12/31/2023
Completion :
12/31/2023
Phase 2
Seagen Inc.
Recruiting
Last update posted :
10/21/2021
Initiation :
10/31/2021
Primary completion :
10/31/2024
Completion :
10/31/2025
BRAF
|
BRAF mutation
|
Keytruda (pembrolizumab) • carboplatin • pemetrexed • SEA-CD40
Phase 1
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
10/25/2021
Primary completion :
12/01/2036
Completion :
12/01/2036
CD22
|
JCAR018
Phase 1/2
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
10/25/2021
Primary completion :
02/28/2026
Completion :
12/31/2026
UGT1A1
|
UGT1A1*28 • UGT1A1*1*1
|
temozolomide • vincristine • PEN-866
Phase 2
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
10/25/2021
Primary completion :
01/31/2025
Completion :
12/31/2025
PD-L1
|
HER-2 positive
|
Keytruda (pembrolizumab) • Anktiva (inbakicept) • PD-L1.t-haNK
Phase 3
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
10/21/2021
Initiation :
08/11/2021
Primary completion :
04/03/2022
Completion :
04/03/2022
Phase 2a
ViiV Healthcare
Recruiting
Last update posted :
10/21/2021
Initiation :
06/22/2021
Primary completion :
12/08/2022
Completion :
11/08/2023
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
04/28/2021
Primary completion :
04/30/2022
Completion :
04/30/2022
PD-L1 • BRCA1 • BRCA2
|
BRCA1 mutation • BRCA2 mutation
|
Lynparza (olaparib) • Avastin (bevacizumab) • paclitaxel • Imfinzi (durvalumab) • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin)
Phase 2/3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/21/2021
Initiation :
03/19/2021
Primary completion :
03/31/2025
Completion :
03/31/2025
BCL2 • BCL6 • CD4
|
BCL6 rearrangement • BCL2 rearrangement
|
Rituxan (rituximab) • doxorubicin hydrochloride • vincristine • Onureg (azacitidine oral) • Riabni (rituximab-arrx) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • TQB2303 (rituximab biosimilar) • cyclophosphamide intravenous • prednisone delayed-release tablet
Phase 2
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
10/25/2021
Primary completion :
10/31/2023
Completion :
10/31/2027
Phase 3
Amgen
Not yet recruiting
Last update posted :
10/21/2021
Initiation :
12/01/2021
Primary completion :
01/01/2025
Completion :
01/01/2025
FGFR2
|
FGFR2 overexpression • FGFR2b overexpression
|
oxaliplatin • bemarituzumab (FPA-144)
Phase 3
Novo Nordisk A/S
Recruiting
Last update posted :
10/21/2021
Initiation :
06/15/2021
Primary completion :
06/27/2023
Completion :
08/08/2023
Phase 3
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
10/21/2021
Initiation :
07/28/2021
Primary completion :
12/29/2025
Completion :
12/29/2025
PD-L1
|
Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • lenvatinib • oxaliplatin • Levofolinate • levoleucovorin calcium
Phase 1
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
10/25/2021
Primary completion :
12/31/2023
Completion :
12/31/2023
GPC3
|
GPC3 expression
|
fludarabine IV • cyclophosphamide intravenous
Phase 3
Novo Nordisk A/S
Recruiting
Last update posted :
10/21/2021
Initiation :
04/01/2021
Primary completion :
04/07/2028
Completion :
05/26/2028
Phase 1/2
LaNova Medicines Limited
Not yet recruiting
Last update posted :
10/21/2021
Initiation :
10/30/2021
Primary completion :
04/10/2023
Completion :
05/05/2024
MSI • CLDN18
|
MSI-H/dMMR • CLDN18.2 expression • CLDN18.2 positive
|
LM302
Phase N/A
AbbVie
Recruiting
Last update posted :
10/21/2021
Initiation :
02/09/2021
Primary completion :
03/29/2024
Completion :
03/29/2024
Phase 3
Novo Nordisk A/S
Recruiting
Last update posted :
10/21/2021
Initiation :
05/18/2021
Primary completion :
08/09/2024
Completion :
09/09/2025
Phase 2
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
10/21/2021
Initiation :
06/25/2021
Primary completion :
09/19/2024
Completion :
09/19/2024
EGFR • MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • quavonlimab/pembrolizumab (MK-1308A)
Phase 3
AstraZeneca
Recruiting
Last update posted :
10/21/2021
Initiation :
06/30/2021
Primary completion :
09/28/2023
Completion :
06/25/2026
HER-2 • ER
|
ER positive • HER-2 negative
|
Ibrance (palbociclib) • Verzenio (abemaciclib) • letrozole • anastrozole • camizestrant (AZD9833)
Phase 1
AbbVie
Recruiting
Last update posted :
10/21/2021
Initiation :
02/18/2021
Primary completion :
11/25/2025
Completion :
11/28/2026
EGFR
|
EGFR expression
|
Tagrisso (osimertinib) • docetaxel • ABBV-637
Phase 3
Novo Nordisk A/S
Recruiting
Last update posted :
10/21/2021
Initiation :
05/18/2021
Primary completion :
08/09/2024
Completion :
09/09/2025
Phase 1/2
Mersana Therapeutics
Recruiting
Last update posted :
10/21/2021
Initiation :
06/11/2021
Primary completion :
11/01/2023
Completion :
07/01/2024
SLC34A2
|
carboplatin • upifitamab rilsodotin (XMT-1536)
Phase 2
Veru Inc.
Not yet recruiting
Last update posted :
10/21/2021
Initiation :
12/30/2021
Primary completion :
07/30/2022
Completion :
06/30/2023
HER-2 • ER • PGR
|
ER expression
|
Trodelvy (sacituzumab govitecan-hziy) • sabizabulin (VERU-111)
Phase 3
AbbVie
Recruiting
Last update posted :
10/21/2021
Initiation :
08/24/2021
Primary completion :
04/05/2024
Completion :
04/05/2024
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
10/25/2021
Primary completion :
12/01/2022
Completion :
12/01/2023
NF1
|
NF1 mutation
|
Verzenio (abemaciclib)
Phase N/A
General Hospital of Shenyang Military Region
Recruiting
Last update posted :
10/21/2021
Initiation :
03/22/2021
Primary completion :
11/30/2021
Completion :
12/30/2021
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
10/25/2021
Primary completion :
12/01/2025
Completion :
12/01/2026
Phase 1
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
10/25/2021
Primary completion :
07/01/2025
Completion :
07/01/2025
BCL2 • BCL6
|
BCL6 rearrangement • BCL2 rearrangement
|
Rituxan (rituximab) • doxorubicin hydrochloride • etoposide IV • prednisone • Aliqopa (copanlisib) • vincristine • cyclophosphamide intravenous
Phase 2
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
10/25/2021
Primary completion :
08/31/2024
Completion :
12/31/2024
PD-L1 • CD4
|
bintrafusp alfa (M7824)
Phase 1/2
Astellas Pharma Global Development, Inc.
Recruiting
Last update posted :
10/21/2021
Initiation :
07/29/2021
Primary completion :
12/31/2027
Completion :
12/31/2027
EGFR • BRAF • ALK • WT1
|
EGFR mutation • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • ASP7517
Phase 2
BeiGene
Recruiting
Last update posted :
10/21/2021
Initiation :
03/31/2021
Primary completion :
11/01/2023
Completion :
03/01/2024
PD-L1
|
Baize’an (tislelizumab) • ociperlimab (BGB-A1217)
Phase 3
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
10/21/2021
Initiation :
03/29/2021
Primary completion :
11/22/2023
Completion :
11/22/2023
EGFR • BRAF • KRAS • MSI
|
BRAF V600E • MSI-H/dMMR • BRAF V600
|
Keytruda (pembrolizumab) • lenvatinib • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)
Phase 2
California Pacific Medical Center Research Inst...
Recruiting
Last update posted :
10/21/2021
Initiation :
09/20/2021
Primary completion :
03/01/2024
Completion :
03/01/2026
PD-1
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 1/2
Pyramid Biosciences
Recruiting
Last update posted :
10/21/2021
Initiation :
07/20/2021
Primary completion :
06/01/2024
Completion :
06/01/2024
WT1 • EWSR1 • NTRK
|
WT1 expression • NTRK fusion • NTRK positive • WT1 positive
|
PBI-200
Phase 2
Themis Bioscience GmbH
Completed
Last update posted :
10/20/2021
Initiation :
08/22/2018
Primary completion :
01/25/2019
Completion :
11/16/2019
Phase 2
Medical College of Wisconsin
Recruiting
Last update posted :
10/20/2021
Initiation :
10/03/2017
Primary completion :
12/01/2023
Completion :
12/01/2024
Phase 2/3
University of Oxford
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
05/28/2020
Primary completion :
12/31/2021
Completion :
12/31/2021
Phase 3
Merck Sharp & Dohme Corp.
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
05/06/2019
Primary completion :
10/31/2023
Completion :
10/31/2023
PD-L1
|
Keytruda (pembrolizumab) • cisplatin • lenvatinib
Phase 2
National Cancer Institute (NCI)
Suspended
Last update posted :
10/20/2021
Initiation :
04/05/2018
Primary completion :
07/31/2022
Completion :
07/31/2022
EGFR
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
Tagrisso (osimertinib)
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
06/20/2019
Primary completion :
01/01/2027
Completion :
01/01/2027
PD-L1
|
PD-L1 expression
|
Opdivo (nivolumab) • cisplatin • CMAB 819 (nivolumab biosimilar)
Phase 2/3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
02/05/2016
Primary completion :
06/30/2023
Completion :
06/30/2023
BRCA1 • BRCA2 • MUC16 • BRCA
|
BRCA1 mutation • BRCA2 mutation • BRCA mutation
|
Lynparza (olaparib) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin)
Phase 3
Medical College of Wisconsin
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
06/25/2019
Primary completion :
02/01/2023
Completion :
02/01/2024
HLA-DRB1
|
cyclophosphamide intravenous • mycophenolate mofetil • peripheral blood stem cell transplantation • tacrolimus intravenous
Phase 1
MacroGenics
Completed
Last update posted :
10/20/2021
Initiation :
09/25/2018
Primary completion :
09/28/2021
Completion :
09/28/2021
Phase 4
Takeda
Recruiting
Last update posted :
10/20/2021
Initiation :
12/22/2020
Primary completion :
03/31/2026
Completion :
03/31/2026
Phase 1/2
National Cancer Institute (NCI)
Suspended
Last update posted :
10/20/2021
Initiation :
10/05/2021
Primary completion :
08/14/2023
Completion :
08/14/2024
CD4
|
bintrafusp alfa (M7824) • entinostat (SNDX-275) • M-9241
Phase 2
National Cancer Institute (NCI)
Suspended
Last update posted :
10/20/2021
Initiation :
01/31/2020
Primary completion :
10/01/2022
Completion :
10/01/2022
CD4
|
carboplatin • paclitaxel • pevonedistat (MLN4924)
Phase 1
University of Washington
Recruiting
Last update posted :
10/20/2021
Initiation :
11/18/2021
Primary completion :
09/01/2024
Completion :
03/30/2026
HER-2 • PD-L1 • ER • BRCA1 • PGR • BRCA2 • BRCA
|
BRCA1 mutation • BRCA2 mutation
|
Zejula (niraparib) • Jemperli (dostarlimab)
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
05/06/2021
Primary completion :
09/30/2027
Completion :
09/30/2027
CD4
|
cisplatin • gemcitabine • Imfinzi (durvalumab) • doxorubicin hydrochloride • methotrexate • methotrexate IV • Fulphila (pegfilgrastim-jmdb) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Pegcyte (pegfilgrastim biosimilar) • Udenyca (pegfilgrastim biosimilar) • Ziextenzo (pegfilgrastim biosimilar) • liposomal gemcitabine (FF-10832) • vinblastine
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
08/12/2015
Primary completion :
03/31/2022
ROS1
|
Xalkori (crizotinib)
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
05/09/2019
Primary completion :
09/15/2022
Completion :
09/15/2022
PD-L1
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 3
University of Sydney
Recruiting
Last update posted :
10/20/2021
Initiation :
10/14/2021
Primary completion :
12/31/2022
Completion :
12/31/2024
Phase 2
Hoffmann-La Roche
Recruiting
Last update posted :
10/20/2021
Initiation :
01/18/2021
Primary completion :
09/25/2032
Completion :
09/25/2032
BRAF
|
Tecentriq (atezolizumab) • Rozlytrek (entrectinib) • Kadcyla (ado-trastuzumab emtansine) • Alecensa (alectinib) • Gavreto (pralsetinib) • ipatasertib (GDC-0068) • belvarafenib (HM95573) • idasanutlin (RO5503781) • inavolisib (GDC-0077)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
12/23/2016
Primary completion :
12/31/2021
Completion :
12/31/2021
HRD
|
HRD
|
Lynparza (olaparib) • Recentin (cediranib)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
10/25/2021
Primary completion :
12/31/2023
Completion :
12/31/2023
BRAF • KRAS
|
KRAS mutation
|
Mekinist (trametinib) • hydroxychloroquine
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
11/15/2016
Primary completion :
08/31/2022
Completion :
08/31/2022
HER-2 • BRCA1 • BRCA2 • BRCA
|
HER-2 positive • BRCA1 mutation • BRCA2 mutation • BRCA mutation
|
Lynparza (olaparib) • Tecentriq (atezolizumab)
Phase 2
Reistone Biopharma Company Limited
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
12/24/2020
Primary completion :
08/31/2022
Completion :
09/30/2022
Phase 2
The Netherlands Cancer Institute
Recruiting
Last update posted :
10/20/2021
Initiation :
12/04/2018
Primary completion :
12/01/2021
Completion :
02/01/2022
EGFR
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
Erbitux (cetuximab) • Gilotrif (afatinib)
Phase 1/2
The Methodist Hospital Research Institute
Completed
Last update posted :
10/20/2021
Initiation :
11/01/2016
Primary completion :
01/01/2021
Completion :
01/01/2021
HER-2 • ER • PGR
|
HER-2 negative • ER negative • PGR negative
|
docetaxel • Neulasta (pegfilgrastim) • amlodipine besilate • aspirin
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
07/06/2021
Primary completion :
06/01/2025
Completion :
06/01/2025
EGFR • MGMT • TERT
|
EGFR amplification • TERT promoter mutation • TERT mutation
|
Tecentriq (atezolizumab) • Actemra IV (tocilizumab)
Phase N/A
Assistance Publique - Hôpitaux de Paris
Recruiting
Last update posted :
10/20/2021
Initiation :
08/01/2018
Primary completion :
12/15/2022
Completion :
12/15/2022
Phase 3
Hoffmann-La Roche
Completed
Last update posted :
10/20/2021
Initiation :
07/06/2011
Primary completion :
02/01/2016
Completion :
07/30/2021
CD20
|
CD20 positive
|
Rituxan (rituximab) • doxorubicin hydrochloride • Gazyva (obinutuzumab) • prednisone • vincristine • bendamustine • cyclophosphamide intravenous
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
03/12/2019
Primary completion :
01/31/2023
Completion :
01/31/2023
ER • PGR • IL2
|
HER-2 positive
|
Herceptin (trastuzumab) • Tecentriq (atezolizumab) • paclitaxel • docetaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab biosimilar) • Ontruzant (trastuzumab biosimilar) • Ogivri (trastuzumab biosimilar) • EG12014 (trastuzumab biosimilar) • EG-12 • GB221 (trastuzumab biosimilar) • HS627 (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
12/02/2019
Primary completion :
03/01/2023
Completion :
03/01/2023
IDH1 • IDH2
|
IDH2 mutation
|
Lynparza (olaparib) • ceralasertib (AZD6738)
Phase 3
Gilead Sciences
Recruiting
Last update posted :
10/20/2021
Initiation :
03/31/2021
Primary completion :
06/01/2022
Completion :
07/01/2022
Phase 3
Novartis Pharmaceuticals
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
12/20/2012
Primary completion :
04/29/2016
Completion :
03/01/2024
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
07/24/2017
Primary completion :
09/30/2024
Completion :
09/30/2024
ALB
|
Lynparza (olaparib)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
03/30/2018
Primary completion :
07/31/2022
Completion :
07/31/2022
IDH1 • IDH2
|
IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132G • IDH1 R132V • IDH2 R140Q • IDH2 R172 • IDH2 R172G
|
Lynparza (olaparib)
Phase 2
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Recruiting
Last update posted :
10/20/2021
Initiation :
10/08/2021
Primary completion :
12/01/2023
Completion :
06/01/2024
KRAS
|
KRAS expression
|
Avastin (bevacizumab) • capecitabine • Focus V (anlotinib) • oxaliplatin • penpulimab (AK105)
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
11/04/2020
Primary completion :
11/02/2025
Completion :
11/02/2025
CD4
|
Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CMAB 819 (nivolumab biosimilar)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
04/26/2016
Primary completion :
12/31/2021
Completion :
12/31/2021
EGFR • HER-2 • ER • PGR
|
HER-2 expression • ALK mutation
|
Lynparza (olaparib) • Recentin (cediranib)
Phase 2/3
VA Office of Research and Development
Recruiting
Last update posted :
10/20/2021
Initiation :
06/09/2021
Primary completion :
05/30/2025
Completion :
11/03/2025
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
03/09/2020
Primary completion :
12/01/2022
Completion :
12/01/2022
IDH1 • IDH2
|
IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132G • IDH1 R132V • IDH2 R140Q • IDH2 R172 • IDH2 R172G
|
Lynparza (olaparib)
Phase 1
Ascentage Pharma Group Inc.
Recruiting
Last update posted :
10/20/2021
Initiation :
01/09/2020
Primary completion :
12/30/2021
Completion :
12/30/2023
ABL1 • BCR
|
ABL1 T315I
|
olverembatinib (HQP1351)
Phase 2
Albert Einstein College of Medicine
Completed
Last update posted :
10/20/2021
Initiation :
07/01/2008
Primary completion :
01/01/2015
Completion :
02/01/2015
Phase 1
Dana-Farber Cancer Institute
Recruiting
Last update posted :
10/20/2021
Initiation :
09/24/2021
Primary completion :
06/23/2023
Completion :
06/23/2026
CD22
|
CD22 positive
|
Venclexta (venetoclax) • Besponsa (inotuzumab ozogamicin) • Decadron (dexamethasone) • Maxidex (dexamethasone eye drops, suspension)
Phase N/A
University of Calgary
Recruiting
Last update posted :
10/20/2021
Initiation :
07/08/2020
Primary completion :
12/31/2024
Completion :
06/30/2025
Phase N/A
Novartis Pharmaceuticals
Recruiting
Last update posted :
10/20/2021
Initiation :
06/30/2021
Primary completion :
07/31/2026
Completion :
07/31/2026
Phase N/A
Children's Hospital Los Angeles
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
11/01/2021
Primary completion :
05/01/2022
Completion :
11/01/2022
Phase N/A
Manchester University NHS Foundation Trust
Completed
Last update posted :
10/20/2021
Initiation :
03/12/2014
Primary completion :
12/31/2020
Completion :
12/31/2020
Phase 
Norwegian University of Science and Technology
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
10/01/2021
Primary completion :
02/01/2024
Completion :
02/01/2024
Phase 1/2
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
10/25/2021
Primary completion :
12/31/2024
Completion :
12/31/2025
ALB
|
Fotivda (tivozanib)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
12/06/2018
Primary completion :
09/01/2022
Completion :
09/01/2022
CD4
|
Keytruda (pembrolizumab)
Phase N/A
University of Rochester
Recruiting
Last update posted :
10/20/2021
Initiation :
07/19/2021
Primary completion :
03/15/2024
Completion :
03/15/2026
Phase 2/3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
08/17/2020
Primary completion :
04/30/2027
Completion :
04/30/2027
Phase 2
Center for International Blood and Marrow Trans...
Recruiting
Last update posted :
10/20/2021
Initiation :
09/30/2021
Primary completion :
07/01/2024
Completion :
07/01/2024
HLA-DRB1
|
melphalan • fludarabine IV • mesna • busulfan • cyclophosphamide intravenous • mycophenolate mofetil
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
06/12/2017
Primary completion :
06/01/2023
Completion :
06/01/2023
MYCN
|
MYCN amplification
|
temozolomide • irinotecan • Danyelza (naxitamab) • Leukine (sargramostim)
Phase 
Selcuk University
Completed
Last update posted :
10/20/2021
Initiation :
03/15/2019
Primary completion :
03/15/2020
Completion :
03/15/2020
Phase 1
GeneOne Life Science, Inc.
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
11/01/2021
Primary completion :
04/01/2022
Completion :
12/01/2022
Phase 2
Tianjin Medical University Cancer Institute and...
Recruiting
Last update posted :
10/20/2021
Initiation :
02/08/2021
Primary completion :
10/31/2023
Completion :
12/31/2024
HER-2 • BRCA
|
HR positive • HER-2 negative • BRCA mutation
|
AiRuiKa (camrelizumab) • Epidaza (chidamide) • AiRuiYi (fluzoparib)
Phase 2
Sanofi Pasteur, a Sanofi Company
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
10/28/2019
Primary completion :
01/01/2023
Completion :
01/01/2023
Phase 3
Ionis Pharmaceuticals, Inc.
Recruiting
Last update posted :
10/20/2021
Initiation :
06/01/2021
Primary completion :
02/01/2024
Completion :
11/01/2025
Phase 1
ProDa BioTech, LLC
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
11/01/2021
Primary completion :
02/01/2024
Completion :
05/01/2024
Cancer antigen 19-9
Phase 1/2
National Cancer Institute (NCI)
Suspended
Last update posted :
10/20/2021
Initiation :
06/09/2020
Primary completion :
01/30/2022
Completion :
01/01/2023
CD4
|
bintrafusp alfa (M7824) • M-9241 • PDS0101
Phase 1
Zhejiang University
Recruiting
Last update posted :
10/20/2021
Initiation :
10/08/2021
Primary completion :
10/08/2024
Completion :
10/08/2024
Phase 1
Sun Pharma Advanced Research Company Limited
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
10/01/2021
Primary completion :
01/01/2024
Completion :
01/01/2024
HER-2 • ER • CDK4
|
ER positive • HER-2 negative • ER mutation
|
SCO-120
Phase 2
National Cancer Institute (NCI)
Suspended
Last update posted :
10/20/2021
Initiation :
03/29/2019
Primary completion :
01/31/2025
Completion :
01/31/2025
ARID1A
|
MSI-H/dMMR • ARID1A mutation
|
Tazverik (tazemetostat)
Phase 1
AbbVie
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
03/20/2017
Primary completion :
02/12/2022
Completion :
02/12/2022
KRAS
|
KRAS mutation
|
Venclexta (venetoclax) • Avastin (bevacizumab) • 5-fluorouracil • leucovorin calcium • eftozanermin alfa (ABBV-621)
Phase N/A
University Hospital Inselspital, Berne
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
01/01/2022
Primary completion :
09/01/2025
Completion :
09/01/2025
Phase 3
AstraZeneca
Recruiting
Last update posted :
10/20/2021
Initiation :
11/30/2020
Primary completion :
11/28/2025
Completion :
10/29/2027
PD-L1
|
PD-L1 expression
|
Imfinzi (durvalumab)
Phase 1
Zhejiang University
Recruiting
Last update posted :
10/20/2021
Initiation :
11/05/2021
Primary completion :
11/05/2024
Completion :
11/05/2024
Phase 1/2
National Institute of Allergy and Infectious Di...
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
10/25/2021
Primary completion :
06/30/2026
Completion :
06/30/2026
Phase 2
GOG Foundation
Completed
Last update posted :
10/20/2021
Initiation :
12/13/2010
Primary completion :
09/01/2011
Completion :
08/31/2016
CYP1A2 • CYP2D6
|
cisplatin • paclitaxel • elesclomol (STA-4783)
Phase 2
National Cancer Institute (NCI)
Suspended
Last update posted :
10/20/2021
Initiation :
10/11/2019
Primary completion :
12/31/2022
Completion :
12/31/2022
BRCA1 • BRCA2 • MUC16 • BRCA
|
BRCA1 mutation • BRCA2 mutation • BRCA mutation
|
Lynparza (olaparib) • tremelimumab (CP-675206)
Phase 1/2
National Institute of Allergy and Infectious Di...
Enrolling by invitation
Last update posted :
10/20/2021
Initiation :
10/25/2021
Primary completion :
09/09/2026
Completion :
09/09/2026
Phase 2
American Society of Clinical Oncology
Recruiting
Last update posted :
10/20/2021
Initiation :
03/14/2016
Primary completion :
12/31/2023
Completion :
12/31/2024
BRAF
|
ER positive • HER-2 negative • PGR positive
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Gilotrif (afatinib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Rozlytrek (entrectinib) • Yervoy (ipilimumab) • Sutent (sunitinib) • Cotellic (cobimetinib) • Perjeta (pertuzumab) • Verzenio (abemaciclib) • fulvestrant • Stivarga (regorafenib) • Talzenna (talazoparib) • Torisel (temsirolimus) • letrozole • Tukysa (tucatinib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
Phase 2
National Institute of Allergy and Infectious Di...
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
10/14/2020
Primary completion :
12/31/2021
Completion :
12/31/2021
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
07/06/2016
Primary completion :
10/07/2022
Completion :
10/07/2022
BCL2
|
ibrutinib • cytarabine • etoposide IV • melphalan • carmustine • cyclophosphamide intravenous
Phase 3
AIDS Clinical Trials Group
Completed
Last update posted :
10/20/2021
Initiation :
10/01/2013
Primary completion :
03/13/2018
Completion :
08/29/2019
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
05/28/2019
Primary completion :
12/28/2026
Completion :
12/28/2026
TMB
|
cisplatin • carboplatin • Tecentriq (atezolizumab) • etoposide IV
Phase 2
National Institute of Allergy and Infectious Di...
Recruiting
Last update posted :
10/20/2021
Initiation :
07/21/2021
Primary completion :
10/26/2021
Completion :
12/17/2021
Phase 1
Zhejiang University
Recruiting
Last update posted :
10/20/2021
Initiation :
11/05/2021
Primary completion :
11/05/2024
Completion :
11/05/2024
Phase 2
Novo Nordisk A/S
Recruiting
Last update posted :
10/20/2021
Initiation :
08/31/2021
Primary completion :
05/08/2024
Completion :
09/20/2024
Phase 2/3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
08/06/2020
Primary completion :
08/23/2024
Completion :
08/23/2024
PD-L1 • IDH1 • MGMT
|
IDH1 R132H • MGMT promoter methylation
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 1b
Biosplice Therapeutics, Inc.
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
10/01/2021
Primary completion :
07/01/2026
Completion :
07/01/2026
ALK • NTRK
|
EGFR mutation
|
5-fluorouracil • docetaxel • Vectibix (panitumumab) • abiraterone acetate • prednisone • leucovorin calcium • cirtuvivint (SM08502)
Phase 2
Gilead Sciences
Recruiting
Last update posted :
10/20/2021
Initiation :
10/05/2021
Primary completion :
08/01/2022
Completion :
09/01/2026
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
04/12/2019
Primary completion :
02/28/2023
Completion :
02/28/2023
PD-L1 • CD4
|
Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 
University of Arkansas
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
01/01/2022
Primary completion :
12/01/2023
Completion :
07/01/2024
Phase 2
University of Florida
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
02/23/2018
Primary completion :
02/01/2023
Completion :
02/01/2023
MGMT
|
Keytruda (pembrolizumab) • temozolomide
Phase 
University Health Network, Toronto
Recruiting
Last update posted :
10/20/2021
Initiation :
07/01/2020
Primary completion :
09/01/2022
Completion :
09/01/2023
Phase 1b
Amgen
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
12/06/2021
Primary completion :
06/04/2024
Completion :
12/10/2024
Phase N/A
Beth Israel Deaconess Medical Center
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
10/01/2021
Primary completion :
10/01/2025
Completion :
10/01/2025
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
04/16/2021
Primary completion :
01/31/2024
Completion :
01/31/2024
Phase 3
Makerere University
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
03/01/2022
Primary completion :
03/01/2027
Completion :
09/01/2027
Phase 4
Novartis Pharmaceuticals
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
11/05/2021
Primary completion :
07/13/2023
Completion :
12/19/2025
Phase N/A
John Paul II Hospital, Krakow
Recruiting
Last update posted :
10/20/2021
Initiation :
01/31/2020
Primary completion :
12/01/2022
Completion :
03/01/2023
Phase 2
Centre Francois Baclesse
Recruiting
Last update posted :
10/20/2021
Initiation :
12/01/2015
Primary completion :
03/01/2022
Completion :
12/01/2022
Phase 2
Beijing Friendship Hospital
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
10/01/2021
Primary completion :
05/01/2022
Completion :
05/01/2024
Phase N/A
University Hospital, Clermont-Ferrand
Recruiting
Last update posted :
10/20/2021
Initiation :
02/09/2021
Primary completion :
10/30/2021
Completion :
11/30/2021
Phase 2
University Hospital Muenster
Recruiting
Last update posted :
10/20/2021
Initiation :
06/19/2020
Primary completion :
06/01/2024
Completion :
06/01/2024
BCL2 • BCL6
|
BCL6 rearrangement • BCL2 rearrangement
|
Rituxan (rituximab) • Aliqopa (copanlisib)
Phase 2
University of Pennsylvania
Recruiting
Last update posted :
10/20/2021
Initiation :
10/11/2021
Primary completion :
09/01/2026
Completion :
09/01/2026
Phase 1
AstraZeneca
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
02/07/2018
Primary completion :
01/17/2020
Completion :
12/31/2021
STAT3
|
PD-L1 expression • STAT3 expression
|
cisplatin • carboplatin • gemcitabine • Imfinzi (durvalumab) • 5-fluorouracil • Abraxane (albumin-bound paclitaxel) • danvatirsen (AZD9150)
Phase 2
Wuhan Union Hospital, China
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
11/01/2021
Primary completion :
05/01/2022
Completion :
08/01/2024
EGFR • ALK
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK rearrangement
|
Tagrisso (osimertinib)
Phase 2
EQRx, Inc.
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
11/01/2021
Primary completion :
12/01/2023
Completion :
05/01/2026
HER-2 • ER • PGR
|
ER positive • HER-2 negative • PGR positive
|
fulvestrant • letrozole • lerociclib (G1T38)
Phase 2/3
University Hospital, Toulouse
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
10/01/2021
Primary completion :
01/01/2024
Completion :
01/01/2024
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
02/12/2021
Primary completion :
11/12/2022
Completion :
11/12/2022
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
11/02/2020
Primary completion :
02/28/2023
Completion :
02/28/2023
CD4
|
Lynparza (olaparib) • temozolomide
Phase 2
University of Washington
Recruiting
Last update posted :
10/20/2021
Initiation :
11/18/2021
Primary completion :
11/30/2024
Completion :
11/30/2026
Phase 1/2
Verastem, Inc.
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
12/01/2021
Primary completion :
12/01/2023
Completion :
09/01/2025
KRAS
|
KRAS mutation • KRAS G12C • KRAS G12
|
Lumakras (sotorasib) • VS-6766
Phase 2
Uppsala University
Completed
Last update posted :
10/20/2021
Initiation :
09/18/2017
Primary completion :
08/19/2021
Completion :
08/19/2021
CD19
|
autologous 3rd generation CD19-targeting CAR T cell therapy
Phase N/A
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
05/21/2020
Primary completion :
05/31/2023
Completion :
05/31/2023
BRAF
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
04/15/2020
Primary completion :
12/31/2022
Completion :
12/31/2022
PD-L1 • PIK3CA • PTEN
|
PIK3CA mutation • PTEN mutation • PIK3CA E545 • PIK3CA H1047 • PIK3CA E542
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Aliqopa (copanlisib) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase N/A
Medacta USA
Recruiting
Last update posted :
10/20/2021
Initiation :
10/11/2017
Primary completion :
01/01/2023
Completion :
04/01/2023
Phase 2
Omar Nadeem
Recruiting
Last update posted :
10/20/2021
Initiation :
04/09/2021
Primary completion :
02/01/2023
Completion :
02/01/2026
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
07/18/2018
Primary completion :
10/01/2025
Completion :
10/01/2025
LINS1
|
Albumin-L
|
Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
Phase 2/3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
01/17/2019
Primary completion :
12/31/2023
Completion :
12/31/2023
Phase 2b/3
Boehringer Ingelheim
Recruiting
Last update posted :
10/20/2021
Initiation :
12/16/2020
Primary completion :
06/12/2022
Completion :
08/15/2022
Phase 2/3
MacroGenics
Recruiting
Last update posted :
10/20/2021
Initiation :
09/30/2019
Primary completion :
05/01/2024
Completion :
05/01/2026
PD-L1 • MSI
|
PD-L1 expression • HER-2 positive
|
Herceptin (trastuzumab) • capecitabine • oxaliplatin • Margenza (margetuximab) • tebotelimab (MGD013) • retifanlimab (INCMGA0012)
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
11/07/2017
Primary completion :
04/30/2022
Completion :
04/30/2022
BRAF • MSI • MLH1 • MSH6 • MSH2
|
BRAF V600E • MSI-H/dMMR • BRAF V600
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • oxaliplatin • Mvasi (bevacizumab biosimilar) • Zirabev (bevacizumab biosimilar) • leucovorin calcium • Krabeva (bevacizumab biosimilar) • fluorouracil topical • BP102 (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CT-P16 (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • HD204 (bevacizumab biosimilar) • HLX-04 (bevacizumab biosimilar) • MIL 60 (bevacizumab biosimilar)
Phase 2/3
National Cancer Institute (NCI)
Suspended
Last update posted :
10/20/2021
Initiation :
08/07/2019
Primary completion :
04/01/2028
Completion :
04/01/2028
MYC • BCL2 • BCL6
|
BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation
|
Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • etoposide IV • vincristine • Riabni (rituximab-arrx) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • TQB2303 (rituximab biosimilar) • cyclophosphamide intravenous • prednisone delayed-release tablet
Phase 2
Medical College of Wisconsin
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
11/01/2016
Primary completion :
03/01/2022
Completion :
03/01/2023
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
06/03/2020
Primary completion :
12/15/2024
Completion :
12/15/2024
EGFR • PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • gemcitabine • pemetrexed • liposomal gemcitabine (FF-10832)
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
07/19/2019
Primary completion :
03/01/2024
Completion :
03/01/2024
Phase 2
Emory University
Recruiting
Last update posted :
10/20/2021
Initiation :
04/17/2019
Primary completion :
10/26/2022
Completion :
10/01/2023
Phase 1/2
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
10/25/2021
Primary completion :
07/01/2025
Completion :
01/01/2026
SSTR • BRCA
|
SSTR positive
|
Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate)
Phase 
Seno Medical Instruments Inc.
Recruiting
Last update posted :
10/20/2021
Initiation :
09/11/2020
Primary completion :
09/30/2024
Completion :
09/30/2024
HER-2
Phase N/A
Vancouver Coastal Health Research Institute
Recruiting
Last update posted :
10/20/2021
Initiation :
11/15/2020
Primary completion :
07/01/2028
Completion :
07/01/2028
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
08/03/2018
Primary completion :
08/21/2023
Completion :
08/21/2023
ABL1 • TMB • BRCA1 • BRCA2 • MSI • NPM1 • STK11 • POLE • CCND1 • BAP1 • MLH1 • MSH6 • MSH2 • ATRX • POLD1 • SMARCB1 • BRIP1 • CHEK2 • RAD51 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCG • IKBKE • FANCC
|
FANCG mutation
|
Lynparza (olaparib)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
09/04/2018
Primary completion :
09/04/2022
Completion :
09/04/2022
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
02/16/2021
Primary completion :
08/15/2027
Completion :
08/15/2027
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
10/12/2018
Primary completion :
11/30/2021
Completion :
11/30/2021
HRD • CD4
|
HRD
|
Lynparza (olaparib) • Xofigo (radium Ra-223 dichloride)
Phase 1
Aminex Therapeutics, Inc.
Recruiting
Last update posted :
10/20/2021
Initiation :
06/12/2018
Primary completion :
04/01/2022
Completion :
05/01/2022
ALK
Phase 3
AstraZeneca
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
10/21/2015
Primary completion :
01/17/2020
Completion :
01/25/2023
EGFR
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 19 deletion
|
Tagrisso (osimertinib)
Phase N/A
Peter S. Liang, MD MPH
Completed
Last update posted :
10/20/2021
Initiation :
10/11/2018
Primary completion :
12/31/2020
Completion :
12/31/2020
SEPTIN9
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
09/12/2017
Primary completion :
04/02/2024
Completion :
04/02/2024
MSI • MLH1 • MSH6 • MSH2 • CD4
|
MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation • MSH6 expression
|
Tecentriq (atezolizumab) • oxaliplatin • leucovorin calcium • fluorouracil topical
Phase 2
National Cancer Institute (NCI)
Suspended
Last update posted :
10/20/2021
Initiation :
09/22/2020
Primary completion :
07/31/2023
Completion :
07/31/2024
MUC1 • CD4
|
bintrafusp alfa (M7824) • Anktiva (inbakicept) • M-9241 • Panvac-VF (falimarev/inalimarev)
Phase 1
Fred Hutchinson Cancer Research Center
Recruiting
Last update posted :
10/20/2021
Initiation :
03/16/2016
Primary completion :
12/01/2022
Completion :
12/01/2037
HER-2 • ALK • ER • PGR • ROR1
|
EGFR mutation • HER-2 negative • ALK mutation • ROR1 expression
|
fludarabine IV • JCAR024
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
10/30/2020
Primary completion :
05/31/2023
Completion :
05/31/2023
Phase N/A
Barts & The London NHS Trust
Recruiting
Last update posted :
10/20/2021
Initiation :
06/02/2021
Primary completion :
02/01/2022
Completion :
08/01/2022
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
10/25/2021
Primary completion :
12/30/2028
Completion :
12/30/2029
PD-L1
|
PD-L1 expression
|
azacitidine • bintrafusp alfa (M7824)
Phase 3
University of Maryland, Baltimore
Completed
Last update posted :
10/20/2021
Initiation :
09/01/2013
Primary completion :
12/01/2018
Completion :
12/01/2018
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
02/28/2019
Primary completion :
09/30/2022
Completion :
09/30/2022
EGFR • BRAF • PD-L1 • ALK • ROS1
|
PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation
|
Keytruda (pembrolizumab) • carboplatin • pemetrexed
Phase 2
The Netherlands Cancer Institute
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
01/01/2022
Primary completion :
05/30/2022
Completion :
11/30/2022
EGFR • EPCAM
|
Erbitux (cetuximab)
Phase 3
Yale University
Recruiting
Last update posted :
10/20/2021
Initiation :
01/28/2020
Primary completion :
04/01/2024
Completion :
04/01/2024
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
02/07/2020
Primary completion :
02/01/2024
Completion :
02/01/2024
MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
06/07/2019
Primary completion :
06/07/2022
Completion :
06/07/2022
MGMT • SLFN11
|
SLFN11 expression
|
Lynparza (olaparib) • temozolomide
Phase 1
Boehringer Ingelheim
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
06/13/2017
Primary completion :
08/10/2022
Completion :
09/10/2022
EGFR • ALK • TMB • MSI
|
PD-L1 expression • TMB-H • MSI-H/dMMR • PD-L1 overexpression
|
ezabenlimab (BI 754091) • miptenalimab (BI 754111)
Phase 3
Eli Lilly and Company
Recruiting
Last update posted :
10/20/2021
Initiation :
06/22/2020
Primary completion :
01/02/2025
Completion :
04/22/2027
Phase 2
National Institute of Allergy and Infectious Di...
Recruiting
Last update posted :
10/20/2021
Initiation :
10/19/2020
Primary completion :
12/31/2021
Completion :
12/31/2021
Phase 2
Puma Biotechnology, Inc.
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
06/30/2020
Primary completion :
11/30/2021
Completion :
05/31/2022
HER-2 • CRP
|
HER-2 amplification • HER-2 overexpression
|
Nerlynx (neratinib) • capecitabine • loperamide
Phase 4
Joseph Cravero
Recruiting
Last update posted :
10/20/2021
Initiation :
03/02/2017
Primary completion :
12/30/2022
Completion :
01/01/2023
Phase 2
Asan Medical Center
Recruiting
Last update posted :
10/20/2021
Initiation :
01/01/2016
Primary completion :
12/31/2021
Completion :
12/31/2021
KIT • PDGFRA
|
KIT mutation
|
imatinib
Phase 2/3
Genzyme, a Sanofi Company
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
12/18/2015
Primary completion :
10/17/2019
Completion :
10/01/2023
Phase 2
Apexigen, Inc.
Recruiting
Last update posted :
10/20/2021
Initiation :
12/16/2019
Primary completion :
08/12/2022
Completion :
11/12/2022
BRAF
|
BRAF mutation
|
sotigalimab (APX005M)
Phase 1
Medical College of Wisconsin
Completed
Last update posted :
10/20/2021
Initiation :
07/17/2019
Primary completion :
06/01/2021
Completion :
06/30/2021
Phase 2/3
Mack Mitchell
Completed
Last update posted :
10/20/2021
Initiation :
09/01/2013
Primary completion :
10/01/2018
Completion :
10/01/2018
Phase N/A
The Cleveland Clinic
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
11/01/2016
Primary completion :
12/31/2021
Completion :
12/31/2021
Phase 2
AbbVie
Recruiting
Last update posted :
10/20/2021
Initiation :
01/19/2017
Primary completion :
08/01/2025
Completion :
03/17/2026
BCL2
|
BCL2 expression
|
Venclexta (venetoclax) • carfilzomib • dexamethasone
Phase 3
Eli Lilly and Company
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
02/28/2014
Primary completion :
12/31/2022
Completion :
06/30/2023
Phase N/A
University Hospital, Bordeaux
Recruiting
Last update posted :
10/20/2021
Initiation :
10/18/2019
Primary completion :
05/30/2022
Completion :
05/30/2022
Phase 2
Mayo Clinic
Recruiting
Last update posted :
10/20/2021
Initiation :
01/31/2012
Primary completion :
09/01/2022
Completion :
09/01/2022
Phase 2
AstraZeneca
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
05/30/2018
Primary completion :
01/14/2022
Completion :
10/16/2022
EGFR
|
EGFR mutation • EGFR exon 19 deletion
|
Tagrisso (osimertinib)
Phase N/A
University of Miami
Recruiting
Last update posted :
10/20/2021
Initiation :
01/22/2019
Primary completion :
01/01/2022
Completion :
01/01/2022
Phase 2
Washington University School of Medicine
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
11/30/2021
Primary completion :
09/30/2024
Completion :
09/30/2024
CDKN2A • CD8 • IFNG
|
CDKN2A expression
|
CUE-101
Phase 2
Dr. B. Catharine. Craven
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
02/26/2018
Primary completion :
12/01/2022
Completion :
12/01/2022
Phase N/A
Uppsala University
Recruiting
Last update posted :
10/20/2021
Initiation :
11/01/2015
Primary completion :
12/31/2022
Completion :
12/31/2024
IL6
Phase 2
Gynecologic Oncology Group
Completed
Last update posted :
10/20/2021
Initiation :
11/05/2012
Primary completion :
10/31/2015
Completion :
02/19/2019
ALB
|
cisplatin • dalantercept (ACE-041)
Phase N/A
UMC Utrecht
Recruiting
Last update posted :
10/20/2021
Initiation :
10/01/2004
Primary completion :
06/01/2022
Completion :
08/01/2023
Phase 1
RemeGen Co., Ltd.
Recruiting
Last update posted :
10/20/2021
Initiation :
10/01/2021
Primary completion :
12/01/2021
Completion :
02/01/2022
CLDN18
|
R118 • RC118
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
07/09/2019
Primary completion :
05/31/2024
Completion :
05/29/2026
KRAS • PTEN • IGH • FBXW7
|
KRAS mutation • PTEN mutation • FBXW7 mutation
|
sirolimus • fludarabine IV • busulfan • cyclophosphamide intravenous • mycophenolate mofetil
Phase N/A
Takeda
Recruiting
Last update posted :
10/20/2021
Initiation :
03/16/2020
Primary completion :
12/01/2024
Completion :
12/01/2024
HRD • BRCA
|
HRD • BRCA mutation
|
Zejula (niraparib)
Phase N/A
University of British Columbia
Enrolling by invitation
Last update posted :
10/20/2021
Initiation :
08/27/2019
Primary completion :
12/31/2025
Completion :
12/31/2026
Phase 1
LaNova Medicines Limited
Recruiting
Last update posted :
10/20/2021
Initiation :
06/16/2021
Primary completion :
03/15/2023
Completion :
03/15/2023
CLDN18
|
CLDN18.2 positive
|
LM-102
Phase N/A
University of California, San Francisco
Recruiting
Last update posted :
10/20/2021
Initiation :
04/02/2018
Primary completion :
05/31/2022
Completion :
05/31/2022
FOLH1
|
FOLH1 expression
Phase 2
Novartis Pharmaceuticals
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
10/30/2021
Primary completion :
07/31/2023
Completion :
07/31/2023
HER-2 • ER • PIK3CA • PGR
|
ER positive • PIK3CA mutation • HER-2 negative
|
Piqray (alpelisib) • fulvestrant
Phase N/A
MorphoSys AG
Completed
Last update posted :
10/20/2021
Initiation :
04/01/2020
Primary completion :
05/07/2021
Completion :
05/07/2021
CD19
|
Revlimid (lenalidomide) • Monjuvi (tafasitamab)
Phase 1
AstraZeneca
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
12/27/2018
Primary completion :
01/23/2024
Completion :
01/23/2024
PD-L1
|
cisplatin • carboplatin • gemcitabine • Imfinzi (durvalumab) • Abraxane (albumin-bound paclitaxel) • pemetrexed • oleclumab (MEDI9447) • MEDI5752 • danvatirsen (AZD9150)
Phase 2/3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/20/2021
Initiation :
03/18/2013
Primary completion :
01/01/2027
Completion :
01/01/2027
EGFR • CD4
|
CDKN2A negative
|
Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • docetaxel • KL 140 (cetuximab biosimilar)
Phase 3
GlaxoSmithKline
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
02/15/2021
Primary completion :
05/24/2022
Completion :
05/24/2024
Phase 1a/1b
Boehringer Ingelheim
Recruiting
Last update posted :
10/20/2021
Initiation :
05/21/2018
Primary completion :
03/21/2023
Completion :
06/13/2024
TP53 • MDM2
|
MDM2 amplification
|
BI 907828
Phase 1
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
10/20/2021
Initiation :
10/25/2021
Primary completion :
12/30/2024
Completion :
06/26/2025
Phase 2
H. Lee Moffitt Cancer Center and Research Insti...
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
08/12/2014
Primary completion :
07/19/2017
Completion :
12/01/2021
Phase 3
ADC Therapeutics S.A.
Recruiting
Last update posted :
10/20/2021
Initiation :
09/16/2020
Primary completion :
06/30/2025
Completion :
06/30/2028
BCL2 • BCL6 • CD19
|
BCL6 rearrangement • BCL2 rearrangement • CD19 expression
|
Rituxan (rituximab) • gemcitabine • oxaliplatin • Lonca-T (loncastuximab tesirine)
Phase N/A
Children's Hospital Medical Center, Cincinnati
No Longer Available
Last update posted :
10/20/2021
CD34
|
Zolinza (vorinostat) • Azedra (iobenguane I 131)
Phase 2
Checkmate Pharmaceuticals
Recruiting
Last update posted :
10/20/2021
Initiation :
01/01/2022
Primary completion :
09/01/2023
Completion :
01/01/2024
HER-2 • PGR
|
HER-2 negative • PGR negative
|
Libtayo (cemiplimab) • vidutolimod (CMP-001)
Phase 4
University of Maryland, Baltimore
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
10/24/2013
Primary completion :
06/30/2024
Completion :
06/30/2024
CD8 • IFNG • TNFA
|
CD8 positive
Phase N/A
The Hospital for Sick Children
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
07/04/2017
Primary completion :
11/30/2021
Completion :
03/31/2022
Phase 2b
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
10/20/2021
Initiation :
04/07/2021
Primary completion :
07/10/2024
Completion :
01/08/2025
Phase 1/2
Megan Daly, MD
Active, not recruiting
Last update posted :
10/20/2021
Initiation :
05/20/2019
Primary completion :
12/01/2021
Completion :
07/01/2023
PD-L1 • IL2
|
Keytruda (pembrolizumab)
Phase 1b
National Cancer Institute (NCI)
Suspended
Last update posted :
10/20/2021
Initiation :
05/04/2021
Primary completion :
01/01/2024
Completion :
01/01/2024
HER-2 • PD-L1 • ER • PGR • CD4
|
HER-2 positive • HR negative
|
Kadcyla (ado-trastuzumab emtansine) • bintrafusp alfa (M7824) • entinostat (SNDX-275) • BN-Brachyury
Phase 2
Daiichi Sankyo, Inc.
Recruiting
Last update posted :
10/20/2021
Initiation :
06/03/2021
Primary completion :
12/03/2023
Completion :
03/31/2026
ALK • CD8
|
ALK positive • ALK negative
|
valemetostat (DS-3201)
Phase 2/3
Gilead Sciences
Recruiting
Last update posted :
10/19/2021
Initiation :
07/21/2020
Primary completion :
02/01/2022
Completion :
02/01/2022
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/19/2021
Initiation :
12/04/2020
Primary completion :
03/31/2025
Completion :
03/31/2025
BRCA1 • BRCA
|
BRCA1 mutation • BRCA mutation
|
Keytruda (pembrolizumab) • Lynparza (olaparib) • cisplatin
Phase 1/2
Sanofi Pasteur, a Sanofi Company
Recruiting
Last update posted :
10/19/2021
Initiation :
09/17/2020
Primary completion :
04/28/2023
Completion :
04/28/2023
Phase 2a
Pfizer
Recruiting
Last update posted :
10/19/2021
Initiation :
08/10/2020
Primary completion :
08/30/2022
Completion :
09/28/2022
Phase 2
Ontario Clinical Oncology Group (OCOG)
Recruiting
Last update posted :
10/19/2021
Initiation :
01/29/2020
Primary completion :
12/31/2021
Completion :
12/31/2023
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/19/2021
Initiation :
05/13/2021
Primary completion :
09/30/2022
Completion :
09/30/2022
MSI
|
MSI-H/dMMR
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 1b
Oryn Therapeutics, LLC
Completed
Last update posted :
10/19/2021
Initiation :
03/22/2021
Primary completion :
10/12/2021
Completion :
10/12/2021
Phase 2
Bayer
Active, not recruiting
Last update posted :
10/19/2021
Initiation :
07/06/2017
Primary completion :
01/18/2023
Completion :
02/15/2023
HER-2 • ER • PGR • ATM
|
HR positive • ER positive • HER-2 negative • PGR positive • ATM deletion • ATM expression • ATM positive
|
elimusertib (BAY1895344)
Phase 1
Thomas Jefferson University
Active, not recruiting
Last update posted :
10/19/2021
Initiation :
05/20/2019
Primary completion :
10/15/2022
Completion :
10/01/2023
HER-2 • ER • PGR • BRCA
|
HR positive
|
Lynparza (olaparib)
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
10/19/2021
Initiation :
10/16/2017
Primary completion :
10/31/2022
Completion :
10/31/2022
Phase 1
Eisai Co., Ltd.
Recruiting
Last update posted :
10/19/2021
Initiation :
02/05/2018
Primary completion :
03/31/2023
Completion :
03/31/2023
HER-2
|
HER-2 negative
|
E7130
Phase 3
Veru Inc.
Recruiting
Last update posted :
10/19/2021
Initiation :
10/12/2021
Primary completion :
03/30/2023
Completion :
04/30/2023
HER-2 • ER • AR
|
ER positive • HER-2 negative • AR positive
|
everolimus • fulvestrant • exemestane • Ostarine (enobosarm)
Phase 2
Novartis Pharmaceuticals
Recruiting
Last update posted :
10/19/2021
Initiation :
02/16/2021
Primary completion :
01/04/2024
Completion :
02/15/2024
Phase N/A
AbbVie
Recruiting
Last update posted :
10/19/2021
Initiation :
04/24/2020
Primary completion :
03/31/2024
Completion :
03/31/2024
Phase N/A
Istanbul Saglik Bilimleri University
Completed
Last update posted :
10/19/2021
Initiation :
09/23/2019
Primary completion :
03/03/2021
Completion :
03/03/2021
Phase 2
Abramson Cancer Center of the University of Pen...
Active, not recruiting
Last update posted :
10/19/2021
Initiation :
06/30/2017
Primary completion :
06/30/2023
Completion :
06/30/2023
BRCA1 • BRCA2
|
PALB2 mutation
|
cisplatin • Rubraca (rucaparib)
Phase 1
EMD Serono Research & Development Institute, Inc.
Recruiting
Last update posted :
10/19/2021
Initiation :
05/24/2021
Primary completion :
08/01/2022
Completion :
08/01/2022
CHEK2
|
M4076
Phase 1
Skyline Biosciences
Withdrawn
Last update posted :
10/19/2021
Initiation :
01/01/2022
Primary completion :
04/01/2023
Completion :
05/01/2023
CRP
|
SBS-101 • isotretinoin oral
Phase 3
Astellas Pharma Inc
Active, not recruiting
Last update posted :
10/19/2021
Initiation :
01/15/2018
Primary completion :
07/31/2022
Completion :
10/31/2022
FLT3
|
FLT3-ITD mutation • FLT3 mutation • FLT3 D835 • FLT3 I836
|
cytarabine • Xospata (gilteritinib) • etoposide IV • mitoxantrone • fludarabine IV
Phase 1
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Recruiting
Last update posted :
10/19/2021
Initiation :
07/07/2020
Primary completion :
12/01/2021
Completion :
12/01/2021
HER-2
|
HER-2 overexpression
|
GQ1001
Phase 3
The Netherlands Cancer Institute
Active, not recruiting
Last update posted :
10/19/2021
Initiation :
12/01/2013
Primary completion :
12/01/2018
Completion :
12/01/2022
HER-2
|
HER-2 positive • HER-2 amplification • HER-2 overexpression
|
Herceptin (trastuzumab) • carboplatin • paclitaxel • 5-fluorouracil • Perjeta (pertuzumab) • epirubicin
Phase 2
Eli Lilly and Company
Recruiting
Last update posted :
10/19/2021
Initiation :
11/19/2019
Primary completion :
11/17/2023
Completion :
12/15/2023
Phase N/A
Mayo Clinic
Recruiting
Last update posted :
10/19/2021
Initiation :
09/09/2020
Primary completion :
10/31/2022
Completion :
08/31/2023
Phase 2b
GlaxoSmithKline
Active, not recruiting
Last update posted :
10/19/2021
Initiation :
12/09/2020
Primary completion :
06/03/2021
Completion :
10/29/2021
Phase 1/2
Pennington Biomedical Research Center
Active, not recruiting
Last update posted :
10/19/2021
Initiation :
01/28/2021
Primary completion :
12/01/2021
Completion :
12/01/2021
Phase N/A
Children's Oncology Group
Recruiting
Last update posted :
10/19/2021
Initiation :
10/10/2017
Primary completion :
06/30/2023
Completion :
06/30/2023
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/19/2021
Initiation :
01/07/2019
Primary completion :
07/31/2022
Completion :
07/31/2022
CASP3 • FADD • BIRC2
|
birinapant (TL 32711)
Phase 2
Boehringer Ingelheim
Recruiting
Last update posted :
10/19/2021
Initiation :
04/27/2021
Primary completion :
02/01/2023
Completion :
03/01/2023
Phase 3
Novartis Pharmaceuticals
Recruiting
Last update posted :
10/19/2021
Initiation :
02/16/2021
Primary completion :
11/14/2022
Completion :
12/07/2023
Phase 2
Novartis Pharmaceuticals
Active, not recruiting
Last update posted :
10/19/2021
Initiation :
07/02/2018
Primary completion :
02/27/2020
Completion :
11/04/2021
HER-2
|
HER-2 negative • PGR expression
|
carboplatin • spartalizumab (PDR001) • ieramilimab (LAG525)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/19/2021
Initiation :
01/24/2014
Primary completion :
03/20/2025
CD4
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Adcetris (brentuximab vedotin) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 2
Pfizer
Recruiting
Last update posted :
10/19/2021
Initiation :
06/15/2020
Primary completion :
11/01/2022
Completion :
12/01/2022
Phase 2
Amgen
Completed
Last update posted :
10/19/2021
Initiation :
04/07/2015
Primary completion :
06/26/2017
Completion :
12/25/2020
CD8
|
Imlygic (talimogene laherparepvec)
Phase 3
Eisai Inc.
Active, not recruiting
Last update posted :
10/19/2021
Initiation :
03/27/2019
Primary completion :
09/08/2022
Completion :
08/29/2024
Phase N/A
Biogen
Completed
Last update posted :
10/19/2021
Initiation :
03/10/2021
Primary completion :
06/15/2021
Completion :
06/15/2021
Phase 2
AbbVie
Recruiting
Last update posted :
10/19/2021
Initiation :
11/09/2020
Primary completion :
08/09/2023
Completion :
05/10/2024
Phase N/A
Zhejiang Cancer Hospital
Recruiting
Last update posted :
10/19/2021
Initiation :
01/18/2021
Primary completion :
06/30/2022
Completion :
12/30/2022
HER-2
|
HER-2 positive
|
Irene (pyrotinib)